Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study
Travere's FILSPARI reduced four IgA nephropathy biomarkers in new PROTECT data, adding evidence on kidney protection without proving disease modification.
Pharma & Biotech
Pharma & Biotech
Travere Therapeutics’ $475 million raise puts spotlight on rare disease execution risk
Rare disease pipelines need time and cash. Travere’s $475 million debt deal shows how biotech balance sheets are being rebuilt.